Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
Status:
Withdrawn
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of intra-arterial (IA)
delivery of Dexamethasone and Ketorolac into the arteries supplying the sphenopalatine
ganglion (SPG) - a collection of neurons that plays an important role in headache disorders -
in patients with refractory migraine, cluster headache and trigeminal neuralgia. All patients
must fail standard treatments prior to enrollment in the trial.